Tumorad[®] patent approval in Japan
Spago Nanomedical has received notice of allowance for the company´s patent application including Tumorad[®] product protection in Japan.”The patent covers the nanomaterial that is central for the Tumorad[®]-project. As Japan represent a potentially large market for radionuclide therapies, this approval is important. It also underscores the quality of our innovation and strengthens the commercial prospects of the project”, says Spago Nanomedical CEO Mats Hansen. The patent, titled ”Nanostructures and applications thereof” (application no. 2017-501494), is valid until 2035. With the